Kawazoe A, Yamamoto N, Sugimoto N, Kawakami H, et al. Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort. Clin Cancer Res 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-1768.
PMID: 38295160